Atossa Therapeutics to issue CVR to shareholders tied to priority review voucher
Atossa Therapeutics' board approved a plan to issue one contingent value right (CVR) for each common share, giving shareholders a share of proceeds if the company monetizes its first qualifying rare pediatric disease priority review voucher. No voucher has been awarded and no product candidate has been approved, so no CVR payment is assured.
Key points
- Each CVR would entitle holders to 25% of net proceeds from a qualifying voucher monetization, capped at $50 million in aggregate payments.
- Shareholders of record on a record date to be announced, and shares issued later, would receive one CVR per share.
- CVRs would not trade separately and would expire if no qualifying voucher is awarded by December 31, 2036, unless the Board extends that date.
- Atossa has previously reported disclosed voucher sales of $100 million to $220 million over the preceding 18–24 months, but past sales do not establish the value of any voucher it might receive.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.